Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actonel for bone loss in prostate cancer patients on ADT
NCT00426777Phase 3Completed
- Sponsor
- CMX Research
- Start
- Jan 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of risedronate in osteoporosis, sponsored by CMX Research. Primary endpoint: Bone Mineral Density of the Lumbar Spine at 12 months. Started Jan 2007; status: completed.
02
Drugs
risedronate
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00426777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00426777.